RNK08954

Phase 2Small molecule

RRanok Therapeutics (Hangzhou) Co., Ltd.

RNK08954 is one of 47 small molecule programs targeting Pancreatic Ductal Adenocarcinoma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Pancreatic Ductal AdenocarcinomaActive, not recruiting

Pancreatic Ductal AdenocarcinomaPhase 2

Active, not recruiting

Competition

Competitive Landscape

166 competitors in Pancreatic Ductal Adenocarcinoma

#DrugCompanyPhaseTrials

Gemzar

Johnson & Johnson

Phase 3

28 2

Abraxane

Bristol-Myers Squibb

Phase 3

24 3

Eloxatin

Teva

Phase 3

8 4

Camptosar

Pfizer

Phase 3

4 5

Taxol

Teva

Phase 3

2 6

Adrucil

EElorac, Inc.

Phase 3

5 7

Wellcovorin

EEastern Cooperative Oncology Group

Phase 3

3 8

Xeloda

EEngelhard Arzneimittel GmbH & Co.KG

Phase 3

3 9

Ojjaara

GGlaxo Dba Glaxosmithkline

Phase 3

2 10

Camptosar

EEastern Cooperative Oncology Group

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Recruiting

Pancreatic Ductal Adenocarcinoma

NCT07303465

Phase 1Not yet recruiting

Adult

NCT07334262

Clinical

Trials by Indication[1]

Pancreatic Ductal Adenocarcinoma1 trial

To Evaluate the Safety and Efficacy of RNK08954 in Patients With Metastatic Pancreatic Ductal Adenocarcinoma.

Recruiting·RRanok Therapeutics (Hangzhou) Co., Ltd.·Phase 2·NCT07303465·60 enrolled

Adult1 trial

A Study to Evaluate the Food Effect on RNK08954 in Healthy Participants, and the Mass Balance Study of [14C]RNK08954 in Healthy Adult Male Subjects

Not yet recruiting·RRanok Therapeutics (Hangzhou) Co., Ltd.·Phase 1·NCT07334262·24 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for RNK08954. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — RNK08954 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for RNK08954. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Ranok Therapeutics (Hangzhou) Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: RRanok Therapeutics (Hangzhou) Co., Ltd.

RNK08954

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Pancreatic Ductal Adenocarcinoma1 trial

Adult1 trial

References

Drug Info

Quick Facts

Related News